Oppenheimer is initiating coverage of Sequenom Inc. SQNM with an Outperform rating and a $9 price target.
“Sequenom is a hybrid diagnostics and life science tools company,” Oppenheimer writes. “Revenues are currently derived predominantly from sales of the MassArray system and related consumables. However, the real value of SQNM lies within the developmental Trisomy 21 program.”
Sequenom closed today at $5.62.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.